StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) stock

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.60−0.05 (-1.37%)

Close on Nov 18, 2026Market cap $518.01MP/E 24.5Yield –

Anbio Biotechnology revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $8.65M, up 5.6% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.65M+5.6%
FY2024Dec 31, 2024$8.19M+21.9%
FY2023Dec 31, 2023$6.71M-71.5%
FY2022Dec 31, 2022$23.54M–

More Anbio Biotechnology figures

See a number that looks wrong?